Searched for
YO PHARMA
Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...- Betting big on mid and smallcaps; largecaps most expensive on PEG basis, says Dinshaw IraniHelios Mutual Fund is shifting investments from large companies to mid and small companies. This move follows earnings growth trends where ...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
- Q4 earnings review: Motilal Oswal highlights broad-based beat on estimates, lists 6 sectors that exceeded expectationsMotilal Oswal said Q4 FY26 earnings surpassed expectations, with aggregate profits rising 16% year-on-year against its 8% estimate. Strong ...
- Buy financials, healthcare, and manufactured exports; Pramod Gubbi on investing in a tricky marketIndia's Q4 earnings show recovery signs, with Nifty 100 profits up 13%. However, macro headwinds like rising crude oil prices and a depreci...
- Natco Pharma shares crash 15% after weak Q4 results; net profit tanks 34% YoYNatco Pharma shares plunged after the company reported a steep fall in fourth-quarter profit, revenue and EBITDA. Weak operating margins an...
- Strong revenue growth fails to shield India Inc margins in March quarterCorporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...
- Eicher Motors Q4 Results: Cons profit grows 12% YoY to Rs 1,520 crore, revenue jumps 16%Eicher Motors, the maker of Royal Enfield, posted a 12% rise in net profit for the March quarter of FY26. The company's revenue also saw a ...
- Sun Pharma Q4 Results: Cons profit rises 26% YoY to Rs 2,714 crore; board approves Rs 5/share dividendSun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while re...
- Stocks in news: ITC, LIC, Sun Pharma, Maruti Suzuki, Fino Payments BankBenchmark indices experienced a negative close on Thursday, marked by volatile trade and profit booking. Analysts anticipate the Nifty to c...
- Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formul...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the J...
- Stocks in news: Lenskart, Apollo Hospitals, ZEE, BPCL, HindalcoIndian markets navigated a sideways trend, with analysts urging caution until the 24,000 mark is reclaimed. Key stocks like Lenskart, Apoll...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Gland Pharma shares jump 11% as Q4 profit soars 97% YoY, co announces Rs 20/share final dividendShares of Gland Pharma rallied on Monday after the company reported a 97% YoY surge in Q4 profit and strong revenue growth, driven by its C...
- Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisitionZydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. T...
- Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked targetCipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despit...
- Cipla Q4 profit drops 55% to Rs 555 crore; board recommends Rs 13 dividendCipla's fourth-quarter net profit saw a significant drop of 55 percent year-on-year. For the full financial year, the company's profit also...
- Cipla Q4 Results: Profit falls 55% YoY to Rs 555 crore; co declares Rs 13/sh dividendCipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...
Load More
